Young doctors threaten to go on strike
Young Doctors Association (YDA) Khyber-Pakhtunkhwa chapter has warned of boycott across the province if the provincial government does not improve working conditions of medical graduates and increase their salaries.
Addressing a presser, YDA K-P president Dr Hafeez Orakzai highlighted several issues, including the lack of basic facilities in major hospitals, the flawed health card system, and the increased professional tax on doctors from 30 to 80 percent.
He also pointed out that the Public Service Commission has not made recruitment of doctors for the past six years, and merit-based doctors are being ignored in favor of those with political connections.
Dr Hafiz demanded that house job salaries be increased, doctors' salaries be raised, and timely promotions be ensured.
He also requested that professional people be included in the board of governors and that internal hostels be established in medical colleges to provide accommodation for doctors. Furthermore, he demanded that house officers be paid and provided with specialization slots.
The YDA president paid tribute to the dedication of doctors during the COVID-19 pandemic, earthquakes, and floods, but lamented that they are not being recognized or rewarded.
He requested that doctors who lost their lives during the pandemic be given the Shaheed package, and the COVID-19 funds be utilized for their intended purpose.
Dr Hafiz warned that if their demands are not met, the YDA will be forced to shut down all hospitals in Khyber- Pakhtunkhwa and continue their protest until the health minister resigns.
He urged the government to release funds for doctors and meet their demands to avoid a confrontation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
18 hours ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
Express Tribune
3 days ago
- Express Tribune
US CDC COVID vaccine advisor Dr. Lakshmi Panagiotakopoulos resigns: Reuters
Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed U.S. flag in this illustration taken December 11, 2021. Photo:REUTER Listen to article Pediatric infectious disease expert Dr Lakshmi Panagiotakopoulos of the US CDC resigned on Tuesday as co-leader of a working group that advises outside experts on COVID-19 vaccines and is leaving the agency, said two sources familiar with the move. Panagiotakopoulos said in an email to work group colleagues that her decision to step down was based on the belief she is "no longer able to help the most vulnerable members" of the US population. In her role at the Centers for Disease Control and Prevention's working group of the Advisory Committee on Immunization Practices, she co-led the gathering of information on topics for presentation. Her resignation comes one week after Health Secretary Robert F Kennedy Jr, a long-time vaccine skeptic who oversees the CDC, the Food and Drug Administration and the National Institutes of Health, said the COVID vaccine for healthy children and healthy pregnant women had been removed from the CDC's recommended immunization schedule. The move was a departure from the process in which ACIP experts meet and vote on changes to the immunization schedule or recommendations on who should get vaccines before the agency's director made a final call. The committee had not voted on the changes announced by Kennedy and the CDC does not yet have a permanent director. Two days after Kennedy's announcement, the CDC published a vaccine schedule online saying that COVID-19 vaccines remain an option for healthy children aged 6 months to 17 years when parents and doctors agree that it is needed. It had previously recommended updated COVID vaccines for everyone aged six months and older, following the guidance of the panel of outside experts. Two sources said Panagiotakopoulos did not include a specific reason for her departure. Panagiotakopoulos did not return requests for comment. "Unfortunately for me, this is a personal decision," Panagiotakopoulos wrote in an email to members of the working group that was read to Reuters by a source who received it. "My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role." The committee is scheduled to meet on June 25-27 and is expected to deliberate and vote on recommendations for use of COVID-19 vaccines, according to one of the sources who was not authorized to speak publicly.
Express Tribune
7 days ago
- Express Tribune
Covid resurges in India as active cases near 3,000
Listen to article India is witnessing a fresh surge in Covid-19 cases, with active infections nearing 3,000 nationwide, as Kerala emerges as the worst-hit state followed by Maharashtra and Delhi amid a sharp uptick in cases within just four days, NDTV reported. According to official data released by the Ministry of Health and Family Welfare, the country recorded 2,710 active cases as of May 30, up from 1,010 on May 26 — a nearly threefold increase. Kerala has reported the highest number of cases at 1,147, followed by Maharashtra with 424, and Delhi with 294. Gujarat has also recorded 223 cases. Other states reporting a notable number of infections include Tamil Nadu and Karnataka with 148 cases each, and West Bengal with 116. Rajasthan has recorded 51 cases, while Uttar Pradesh has reported 42. Smaller case numbers have been reported in Puducherry (25), Haryana (20), Andhra Pradesh (16), and Madhya Pradesh (10). Read more: CDC updates COVID vaccine guidance, keeps option open for healthy children Goa reported seven cases, whereas Odisha, Punjab, and Indian Illegallly Occupied Jammu and Kashmir (IIOJK) each reported four. Telangana, Arunachal Pradesh, and Chandigarh reported three cases each, while Mizoram and Assam recorded two cases each. Data from Bihar remains unavailable. At least seven deaths have been linked to the recent spike, though the cause of death remains under assessment in some instances. Among the fatalities, two occurred in Maharashtra and Delhi; both individuals reportedly had serious comorbidities. Except for one case in Punjab, all the deceased were senior citizens, officials said. Health authorities, however, have urged the public not to panic, stating that the current wave consists mostly of mild infections. Indian Council of Medical Research (ICMR) Director General Dr Rajiv Bahl said there is no cause for alarm but emphasised the need for continued vigilance. 'The public need not worry about this new variant of Covid-19. We just need to be vigilant,' he said earlier this week. 'We are not talking about enhanced precautions right now. But if someone is a cancer patient or has immunity problems, then we generally advise them to avoid any infection.' Also read: Covid-19 cases on the rise in India, with 2 new variants detected Genomic surveillance data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG) shows that the most prevalent variant remains JN.1, accounting for 53 per cent of all recent samples. This is followed by the BA.2 variant (26%) and other Omicron sublineages (20%). The report also noted at least one confirmed case of the NB.1.8.1 variant, which is believed to be highly contagious, and four cases of the LF.7 variant — both currently classified by the World Health Organisation (WHO) as Variants Under Monitoring (VUMs). While these subvariants are not yet classified as Variants of Concern (VOCs), they are believed to be driving case spikes in parts of China and Asia.
